Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Biomarkers in Pediatric Heart Failure
 |
NICHD Archive
Note: Information on this page was accurate at the time of publication.
This page is no longer being updated. |
June 28, 2018 (Noon - 1:30 p.m. ET)
Sponsor/Co-Sponsor(s)
Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), Best Pharmaceuticals for Children Act (BPCA), NICHD
Purpose
Cardiomyopathy during infancy and childhood can lead to death in infants and children. It also contributes to cardiomyopathies in adults. Cardiomyopathy is the leading cause of heart transplant for children and teenagers and results in considerable health care costs.
Steven E. Lipshultz, M.D., FAAP, FAHA, will discuss causes, risk factors and biomarkers for infants and children with cardiomyopathy and heart failure, as well as preventive strategies that may improve outcomes.
Contact
George Giacoia, OPPTB, NICHD
Phone: (301) 496-5589
E-mail: giacoiag@mail.nih.gov
Please note: Views expressed during NICHD-sponsored events do not necessarily reflect the opinions or the official positions of NICHD, NIH, or HHS.